Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Declares Quarterly Cash Dividend
Mylan Declares Quarterly Cash Dividend PITTSBURGH--(BUSINESS WIRE)--March 22, 2004--Mylan Laboratories Inc. (NYSE: MYL) announced today that the regular quarterly cash dividend of $.03 per share will be payable on April 15, 2004, to shareholders of record at the close of business on March 31, 2004.
View HTML
Toggle Summary Mylan Laboratories Appoints New Vice President of Human Resources
Mylan Laboratories Appoints New Vice President of Human Resources PITTSBURGH--(BUSINESS WIRE)--March 11, 2004--Mylan Laboratories Inc. (NYSE: MYL) is pleased to announce the appointment of Collette Taylor as Vice President of Human Resources. Ms. Taylor will be responsible for leading all human
View HTML
Toggle Summary Mylan Receives FDA Approval for Benazepril Hydrochloride Tablets and Benazepril Hydrochloride and Hydrochlorothiazide Tablets
Mylan Receives FDA Approval for Benazepril Hydrochloride Tablets and Benazepril Hydrochloride and Hydrochlorothiazide Tablets PITTSBURGH--(BUSINESS WIRE)--Feb. 11, 2004--Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval
View HTML
Toggle Summary Appellate Court Stays Injunction in Mylan's Paclitaxel Case
Appellate Court Stays Injunction in Mylan's Paclitaxel Case PITTSBURGH--(BUSINESS WIRE)--Feb. 6, 2004--On December 23, 2003, Mylan Laboratories Inc. (NYSE: MYL) reported that the U.S. District Court for the Western District of Pennsylvania had entered judgment in favor of NaPro Biotherapeutics,
View HTML
Toggle Summary Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of 'Approvable' Letter for EMSAM
Mylan Laboratories and Watson Pharmaceuticals Announce Receipt of 'Approvable' Letter for EMSAM PITTSBURGH & CORONA, Calif.--(BUSINESS WIRE)--Feb. 2, 2004--Mylan Laboratories Inc. (NYSE:MYL) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that Somerset Pharmaceuticals, Inc.
View HTML
Toggle Summary Mylan Reports Record EPS, Revenues and Net Earnings for the Third Quarter of Fiscal 2004; Mylan Announces Earnings Guidance for Fiscal 2005
Mylan Reports Record EPS, Revenues and Net Earnings for the Third Quarter of Fiscal 2004; Mylan Announces Earnings Guidance for Fiscal 2005 PITTSBURGH--(BUSINESS WIRE)--Jan. 29, 2004--Mylan Laboratories Inc. (NYSE: MYL) -- Quarterly Financial Highlights -- Record Third Quarter Diluted Earnings Per
View HTML
Toggle Summary Mylan Receives FDA Approval for New Strength -25mg- Metoprolol Tartrate
Mylan Receives FDA Approval for New Strength -25mg- Metoprolol Tartrate PITTSBURGH--(BUSINESS WIRE)--Jan. 22, 2004--Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application,
View HTML
Toggle Summary Mylan Announces Conference Call Date for Third Quarter Fiscal 2004 Financial Results and Guidance for Fiscal 2005
Mylan Announces Conference Call Date for Third Quarter Fiscal 2004 Financial Results and Guidance for Fiscal 2005 PITTSBURGH, Pa.--(BUSINESS WIRE)--Jan. 20, 2004--Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its third quarter fiscal 2004 financial results and guidance
View HTML
Toggle Summary Mylan Receives FDA Approval for Metolazone Tablets
Mylan Receives FDA Approval for Metolazone Tablets PITTSBURGH--(BUSINESS WIRE)--Dec. 24, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Metolazone Tablets USP, 2.5 mg.
View HTML
Toggle Summary Mylan Updates Litigation Status on Paclitaxel
Mylan Updates Litigation Status on Paclitaxel PITTSBURGH--(BUSINESS WIRE)--Dec. 23, 2003--Mylan Laboratories Inc. (NYSE:MYL) today reported that the U.S. District Court for the Western District of Pennsylvania has entered judgment in favor of Napro BioTherapeutics, Inc.
View HTML